Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy. (1st March 2023)

• Record Type: Journal Article
• Authors: Lubega, Joseph; Kim, Taylor O.; Airewele, Gladstone; Grimes, Amanda; Bulsara, Shaun; Peckham, Erin; Wanless, Sebastian R.; Haq, Heather; Elyanu, Peter; Musoke, Philippa; Lumumba, Mwita; Kekitiinwa, Adeodata; Matshaba, Mogomotsi; Scheurer, Michael; Despotovic, Jenny
• Is Part Of: AIDS. Volume 37:Number 3(2023)
• Page Start: 413
• Page End: 421
• Publication Date: 2023-03-01
• Subjects: biomarker -- children living with HIV -- combination antiretroviral therapy -- platelets -- sub-Sahara Africa -- thrombocytopenia -- thrombocytosis; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003387
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Objectives: To establish the incidence, risk factors and correlation with survival of thrombocytopenia and thrombocytosis (T/T) among children with HIV infection (CWH). Design: A retrospective nested case control study of patients 0–18 years in five Baylor International Pediatric AIDS Initiative (BIPAI) centers in sub-Sahara Africa, 2004–2014. Methods: Clinical and laboratory variables including complete blood counts (CBC) were extracted from the BIPAI electronic medical record system. Incident cases of T/T were identified and frequency-matched on follow-up time with controls with normal platelets. We calculated the prevalence and incidence density of T/T and used conditional logistic regression to evaluate their association with selected clinical variables. We constructed Kaplan–Meier curves and a Cox proportional hazards model to evaluate the impact of T/T on survival. Results: Two thousand, one hundred and nine children were sampled. The incidence density of thrombocytopenia was 1 per 57.9 (95% confidence interval [CI] 50.3–66.8) CWH-years. Thrombocytopenia was higher in children with WHO Stage III/IV, lower in children on zidovudine, and had no association with use of lamivudine or nevirapine, CD4 + suppression, age, and nutrition status. Thrombocytopenia was independently associated with 2.2-fold higher mortality (95% CI 1.62–3.08). The incidence density of thrombocytosis was 1 per 11.4 (95% CI 10.7–12.1) CWH-years. Thrombocytosis was associated with higher CD4 + cell count, younger age, and use of lamivudine or nevirapine, and did not impact survival. Conclusions: Platelet count is a clinically valuable biomarker of HIV clinical progression and mortality. Laboratory studies are necessary to elucidate the mechanisms of T/T.